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Abstract
Purpose: Resistance to antiangiogenic therapy is an important clinical problem. We examined whether resistance occurs at
least in part via reversible, physiologic changes in the tumor, or results solely from stable genetic changes in resistant tumor
cells.
Experimental Design: Mice bearing two human RCC xenografts were treated with sorafenib until they acquired resistance.
Resistant 786-O cells were harvested and reimplanted into naı ¨ve mice. Mice bearing resistant A498 cells were subjected to a
1 week treatment break. Sorafenib was then again administered to both sets of mice. Tumor growth patterns, gene
expression, viability, blood vessel density, and perfusion were serially assessed in treated vs control mice.
Results: Despite prior resistance, reimplanted 786-O tumors maintained their ability to stabilize on sorafenib in sequential
reimplantation steps. A transcriptome profile of the tumors revealed that the gene expression profile of tumors upon
reimplantation reapproximated that of the untreated tumors and was distinct from tumors exhibiting resistance to
sorafenib. In A498 tumors, revascularization was noted with resistance and cessation of sorafenib therapy and tumor
perfusion was reduced and tumor cell necrosis enhanced with re-exposure to sorafenib.
Conclusions: In two RCC cell lines, resistance to sorafenib appears to be reversible. These results support the hypothesis
that resistance to VEGF pathway therapy is not solely the result of a permanent genetic change in the tumor or selection of
resistant clones, but rather is due to a great extent to reversible changes that likely occur in the tumor and/or its
microenvironment.
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Introduction
A major advance in the treatment of renal cell carcinoma
(RCC) over the last few years has been the introduction into
clinical practice of antitumor agents that function primarily as
inhibitors of vascular endothelial growth factor (VEGF)-driven
angiogenesis. The prospect that VEGF receptor (VEGFR)
antagonists might be particularly useful in the treatment of RCC
– especially the clear cell variant - is predicted from the genetic
alterations peculiar to the disease. Approximately 60% of clear cell
RCC lack a functional von Hippel-Lindau (VHL) gene as a result
of biallelic loss, mutation or hypermethylation [1]. The VHL gene
encodes an E3 ubiquitin ligase involved in the oxygen-dependent
ubiquitination and proteasomal degradation of HIF-1a and HIF-
2a, subunits of transcriptional factors involved in the expression of
VEGF and other hypoxia-driven genes. The loss of VHL results in
the accumulation of HIF (even in normoxic conditions) and the
overproduction of VEGF and various other factors. This feature of
clear cell RCC is thought to account for the initial sensitivity of
these tumors to VEGF pathway antagonists.
Sorafenib is a multi-tyrosine kinase inhibitor (TKI) whose
targets include VEGFR2 and its activity is thought to be based on
its action on this target. Sorafenib administration significantly
prolonged median progression free survival (PFS) from 2.8 to 5.5
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involving cytokine refractory patients with advanced RCC [2].
Based on these data, sorafenib received FDA approval in late
2005. Subsequently the VEGF pathway blockers sunitinib,
bevacizumab and pazopanib were also shown to have sufficient
benefit in patients with advanced RCC to merit FDA approval [3].
Although these results are encouraging, there are few if any
complete or durable responses to either sorafenib or the other
VEGF pathway blockers. Typically tumors develop resistance to
sorafenib within a median of 5–9 months, at which point tumor
growth resumes even with the continued administration of the
drug. While a recent randomized placebo controlled phase III trial
reported that the mTOR inhibitor everolimus delayed PFS in
patients with sunitinib and/or sorafenib refractory RCC relative to
placebo from 1.9 to 4.0 months, there is currently no established
consensus for the best treatment approach for patients with RCC
that has acquired resistance to sunitinib or sorafenib [4]. In
particular, higher response rates and longer PFS have been
reported for patients receiving other VEGF pathway blockers, e.g.
axitinib after disease progression on sorafenib, or sunitinib after
disease progression on bevacizumab [3,5–6].
Resistance could be accompanied by a reversible change in the
tumor or could involve a more permanent genetic change in the
tumor cells or endothelial cells. While tumors such as lung cancer
and chronic myelogenous leukemia develop resistance by a
mutation in key signaling pathways in the majority of the
malignant cells [7,8] there is no current available data regarding
whether RCC resistance is accompanied by similar tumor cell
mutations. Moreover, as the target of sorafenib is most likely the
tumor endothelium, it is unlikely that a mutation in this non-
malignant population would occur. Furthermore, although the
mechanism for acquired resistance to VEGF pathway blockade
has yet to be firmly established, the observation that tumors retain
their sensitivity to VEGFR inhibitors suggests that permanent
changes within the tumor do not universally occur. To address this
question, we studied the reversibility of resistance of RCC to
sorafenib in two murine human tumor xenograft models.
Results
Resistance to sorafenib is reversible
We have previously described a model in which the growth of
murine RCC xenografts develops resistance to sorafenib as seen in
RCC patients. Specifically, we note a period of tumor stabilization
after initiation of therapy, defined as time required for the longest
tumor diameter to increase by 20% (growth from 12 mm
treatment start size to 14 mm) similar to RECIST criteria in
patients. This period is followed by a period of more rapid growth
similar to the acquired resistance that is seen in patients with RCC
[9]. This growth pattern contrasts to the fairly constant growth
rate exhibited by untreated tumors. We used this xenograft model
to test the reversibility of the resistant phenotype. Untreated
tumors (n=9) grew by 2 mm in 2.6+/21.2 day while sorafenib
treatment (n=10) led to a 4.9+/21.5 day period of relative tumor
stability (P=0.0029) (Table 1 and Figure 1 A and B).
We then disaggregated tumors excised at the time of sorafenib
resistance and reimplanted the cells into naı ¨ve host mice. As shown
in Table 1 and Figure 1, the reimplants of previously resistant 786-
O cells exhibited a slower growth rate with the initiation of
sorafenib treatment (8.6+/23.1 days period of stabilization), in a
manner similar to tumors derived from the sorafenib-responsive
parent line (Table 1 and Figure 1C).
Moreover, when the reimplanted tumors that had become
resistant a second time were disaggregated and reimplanted into
naı ¨ve hosts, they maintained their ability to respond to sorafenib a
third time with a period of tumor stabilization of 9.7+/23.8 days
(n=10) (Figure 1D). While the reimplanted tumors seemed to
stabilize in response to sorafenib for slightly longer after
reimplantation, the tumor growth rate prior to initiation of
treatment was similar in the untreated and previously treated
xenografts. Specifically, the time to grow from 7 mm to the
treatment initiation size of 12 mm was not significantly different
among the groups (Table 1). These data support the hypothesis
that resistance to sorafenib therapy is at least in part reversible.
Resistance is accompanied by reversible changes in gene
expression
To determine if the changes in gene expression associated with
the development of resistance were also reversible and in effort to
identify genes that are associated with resistance, total RNA was
isolated from untreated tumors harvested at 12 mm, at treatment
day 3, treatment resistant (tumors that had grown to 20 mm
sacrifice size despite continued treatment), and reimplanted
untreated tumors after one and two reimplantations harvested at
12 mm. Gene expression profiling was performed using a
comprehensive Affymetrix platform that measures more than
54,000 well-characterized human transcripts and variants, includ-
ing 38,500 well-characterized human genes. The expression
profiling was performed on at least four tumors from each group.
The heterogeneity in the transcription profile of the tumors was
identified by unsupervised clustering reflecting the global similar-
ities between the samples (Figure 2A). The unsupervised clustering
was performed using all the transcripts that depict a 1.5 fold
change in 20% of the arrays used in the experiment. Unsupervised
clustering demonstrated the highest similarity within the biological
replicates from each group and the least similarity between the
untreated (A, A1, A2) and the treated tumors (C, D). Hierarchical
clustering of all samples demonstrated a clear distinction between
untreated and on treatment samples. This finding is consistent
with the hypothesis that the majority of changes induced in a
tumor with sorafenib treatment and, in particular, after the
development of sorafenib resistance do not represent permanent
changes in the tumors.
The heat map shown in Figure 2B depicts the pattern based
comparison of the expression values of 985 unique genes that are
significantly differentially expressed in one or more of the
following groups: untreated vs. resistant (626), untreated vs.
reimplanted (115) or reimplanted vs. resistant tumors (555). The
sample wise clustering depicts three different groups correspond-
ing to these biologic traits (horizontal axis). The gene-wise
clustering (vertical axis) depicts five major clusters in gene
expression profile: Clusters I (505 genes) & IV (235 genes)
represent the genes whose expression is altered at resistance and
reverts with reimplantation, while clusters II, III and V (161, 29
and 55 genes, respectively) represent differentially expressed genes
whose expression does not revert toward baseline with reimplan-
tation. Thus, ,75% of genes whose expression is altered with
resistance appear to revert to baseline with reimplantation.
To better identify the genes that represent the most likely
contributors to the reversible component of acquired resistance to
sorafenib therapy, we generated a Venn Diagram comparing the
various groups (Figure 2C). Also in Figure 2C, we included genes
that were differentially expressed at day 3 of sorafenib treatment to
identify and eliminate the confounding factor of sorafenib
treatment from the subset of differentially expressed genes at
resistance that revert with reimplantation. Out of 626 transcripts
that differ in resistant tumors as compared untreated controls, 120
were also differentially expressed at day 3 of therapy and thus may
Resistance to Antiangiogenic Therapy Is Reversible
PLoS ONE | www.plosone.org 2 April 2011 | Volume 6 | Issue 4 | e19144represent the effect of sorafenib treatment on the tumors. Similarly
out of 555 transcripts significantly modulated in resistant tumors as
compared to reimplanted tumors, 70 were also found significantly
altered at day 3. All told, 168 transcripts were identified as
differentially expressed in resistant tumors as compared to
untreated as well as resistant as compared to reimplanted tumors
and to not be significantly modulated at day 3. These 168 genes,
therefore, represent the most likely contributors to the reversible
component of acquired resistance to sorafenib therapy and thus,
may represent a ‘‘resistance signature’’.
To validate the microarrays results, we performed RT-PCR
analysis on four genes from the 168 genes that were significantly
overexpressed at resistance but not at day 3 (ANGPTL4, MMP1,
SERPINE 1 and NRP2); and 2 genes from the 70 genes that were
modulated with treatment and resistance (ARG2 and INSIG1). In
all cases the relative expression assessed by PCR correlated with
the relative expression levels noted in the expression profiling
analysis (Figure 2D).
To gain insights into the broad underlying biology of resistance,
gene ontology enrichment analysis was performed on the resistance
signature (168 genes) [10]. The top biological processes and
metabolic functions that are enriched in the set are shown in
Figure 3. Allthese gene ontology categories are significantly affected
(p,0.001). The most highly enriched categories included blood
Figure 1. Growth curves of 786-O tumors. Mice with no treatment (A) (n=9), treated with sorafenib (B) (n=10), reimplanted into naı ¨ve hosts (C)
(n=5) and after a second reimplantation (D) (n=10). Treatment was started at day 0 and in all tumors treated with sorafenib (treatment naı ¨ve (B), and
reimplanted resistant tumors (C and D)) there is a period in which the tumors exhibit stabilization of growth (indicated by arrows and quantified in
Table 1). X axis represents days on sorafenib and Y axis represents long tumor axis (mm). Average tumor size and standard deviation is shown in
growth curves.
doi:10.1371/journal.pone.0019144.g001
Table 1. Tumor growth pre and post therapy.
Time to reach 12 mm(pretreatment
growth rate) (days)
Time to grow from 12–14 mm(length
of tumor plateau) (days)
Untreated (n=9) 13.8+/26.6 2.6+/21.2*
Sorafenib treated (n=10) 15.5+/26.3 4.9+/21.5* {
Sorafenib treatment after
reimplantation (n=5)
14.0+/25.0 8.6+/23.1 {{
Sorafenib treatment after second
reimplantation (n=10)
9.3+/23.2 9.7+/23.8{
P.0.09 for all comparisons *P=0.0029, {P=0.051, { P=0.56
The time to grow by 2 mm is longer in the initial treated tumors vs. the untreated tumors (P=0.0029). All comparisons were performed by Student’s T test.
doi:10.1371/journal.pone.0019144.t001
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development. The angiogenesis group represents 41 discrete genes.
ANGPTL4 and NRP2 are included in the angiogenesis gene
ontogeny groups and as mentioned were validated by RT-PCR.
Consistent with gene expression findings, a decrease in CD34
positive blood vessels was noted early in therapy, began to
reemerge with resistance [8] and approached the pretreatment
level with reimplantation (data not shown).
Figure 3. Gene ontology based enrichment analysis. Enrichment analysis of genes that are commonly differentially expressed in untreated vs.
resistant and reimplanted vs. resistant tumors. The analysis was performed using DAVID software. The X axis represents the gene ontology categories
and Y axis –log of the EASE score. The P value depicts the significance of enrichment, smaller is the P value more significant will be the enrichment.
The most highly enriched geneontology categories included blood vessel morphogenesis, angiogenesis and blood vessel/vasculature development.
doi:10.1371/journal.pone.0019144.g003
Figure 2. Transcriptional profiling analysis of sorafenib treated tumors. A) Unsupervised Pearson Correlation based cluster of untreated
tumors harvested at 12 mm (A), at treatment day 3 (C), treatment resistant (tumors that had grown to 20 mm sacrifice size despite continued
treatment) (D), and reimplanted untreated tumors after one and two reimplantations harvested at 12 mm (A1 and A2) after normalizing the data. The
treated tumors (D,C) form a separate cluster from control and reimplanted tumors. B) Cologram depicting the different expression patterns of the
genes that are either differentially expressed in untreated vs. resistant or reimplanted vs. resistant tumors. The columns represent the samples and
rows represent the genes. Gene expression is shown with pseudocolor scale (23 to 3) with red denoting high expression level and green denoting
low expression level of gene. The Genes depict five major expression patterns (marked I to V). C) Venn diagram indicating overlap between
differentially expressed genes untreated vs resistant, untreated vs responsive, untreated vs. reimplanted and reimplanted vs. resistant. The
differentially expressed genes are extracted using Significantly Analysis of Microarray data (SAM) approach. The green circle shows the 626 transcripts
are changed in resistant tumors as compared to untreated tumors. The overlap of the green and pink circles shows the 120 genes that are also
differentially expressed at day 3 of therapy. The blue circle shows the 555 transcripts that are differentially expressed in reimplanted as compared to
resistant tumors and the overlap of the blue and pink circles show the 70 of the 553 that are altered at day 3 (Responsive). 168 genes are commonly
differentially expressed in the untreated and reimplanted tumors as compared to resistant tumors and not changed at day 3 of therapy and are
circled. D) Validation of 6 resistance related genes was conducted using untreated, resistant and day3 treatment samples (n=3 per group). The
graphs represent the statistical analyzes of relative mRNA levels after normalization for 18S rRNA levels. The results are expressed using floating bars
representing the minimum and maximum values in the group with a line representing the mean. (* P,0.05, ** P,0.001, by Unpaired Student’s T test)
ANGPTL4, MMP1, SERPINE1 and NRP2 were significantly upregulated at resistance but not at day 3 in the gene expression profiling. ARG2 and INSIG1
were increased at day 3 and then decreased at resistance. The PCR showed results similar to transcriptional profiling.
doi:10.1371/journal.pone.0019144.g002
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tumor blood flow
To extend these findings and to confirm our results in a second
RCC cell line, mice harboring tumors derived from A498 cells (a
VHL deficient RCC cell line) were treated with sorafenib
according to 3 schedules. In the first two groups, treatment was
initiated at 12 mm and stopped when the tumor long axis reached
14 mm and then either resumed when the tumors increased by
another 2 mm or continued to be withheld. In the third group,
sorafenib was initiated at 12 mm and not stopped. The time for
tumors to grow from 12 -was similar for all treatment arms (n=12)
but the time to grow by another 2 mm from the start of the second
treatment was shorter in the arm in which sorafenib was stopped
and not restarted (Figure 4D). We did not detect a significant
difference in tumor growth rate from the time of sorafenib re-
initiation in the mice with discontinuous treatment relative to
those who received continuous treatment, (Figure 4D); however,
we did note a marked decrease in viable tumor and increase in
tumor necrosis with the reintroduction of sorafenib (A) compared
to the other two arms (B). As shown in Figure 4C the total area of
necrosis of all tumors retreated with sorafenib was 55% and the
necrosis in the tumors that were not re-exposed to drug was 4%
(n=4 for each arm, P=0.0027). Moreover, the percent of necrosis
of in the tumors in which sorafenib was stopped was similar to that
in the untreated control tumors, while the tumors exposed to
continuous sorafenib appeared to exhibit less necrosis than was
seen with the reintroduction of sorafenib (30% vs 55%
respectively, P=0.19).
To further characterize the reversibility of response to sorafenib,
serial imaging was performed to assess tumor perfusion during
intermittent therapy. As shown in Figure 5, initial treatment with
sorafenib led to a reduction in perfusion after 1 week (119.2
decreased to 41.3 ml/min/100 g). When sorafenib was stopped at
the time of resistance, tumor perfusion increased (from 38.4 to
86.9 ml/min/100 g); however, 1 week after resumption of
sorafenib tumor perfusion was again decreased (from 86.9 to
27.2 ml/min/100 g). This trend was seen in independent imaging
series performed in 2 animals receiving the discontinuous
Figure 4. Pathologic analysis of A498 tumors receiving two different regimens of sorafenib. Representative H&E stain showing tumor
necrosis in a tumor from a mouse treated with sorafenib at 12 mm and in which sorafenib was stopped when the tumor became resistant (14 mm)
and then restarted after the tumor increased from 14 to 16 mm (A: sorafenib restart) and a tumor from a mouse in which sorafenib was started and
stopped at the same timepoints but not restarted on therapy at 16 mm (B: sorafenib stop) is shown. Both specimens were harvested when tumors
reached 20 mm. The area of necrosis (N) is much more prominent in the tumor in which sorafenib was restarted and this was quantitated and shown
in C (N=3–4 for each arm; P=0.0027). D shows the timing of growth of the tumors from the 3 arms.
doi:10.1371/journal.pone.0019144.g004
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sorafenib, after a period off drug, appear to become resensitized to
the antiangiogenic effects of the drug and undergo extensive tumor
necrosis with reintroduction of therapy.
Discussion
VEGF pathway blockade is an effective treatment for patients
with advanced RCC. However, while the multikinase and
VEGFR2 inhibitor sorafenib provides tumor stabilization to a
significant proportion of patients, resistance to therapy is inevitable
and remains poorly understood. We show evidence in a mouse
model that resistance to sorafenib does not appear to result
exclusively (or possibly at all) from a stable genetic mutation, as
seen with resistance of lung cancer to erlotinib or CML to imatinib
[7,8]. Instead, our results support the hypothesis that acquired
resistance to VEGFR antagonists is mechanistically distinct and at
least partially mediated by reversible changes in gene expression
patterns within the tumor cells and/or microenvironment. In
particular, as we show that tumors restore their sensitivity to
VEGF blockade after either reimplantation in a naı ¨ve host, or a
drug holiday, at least a component of the resistance phenotype is
reversible. Therefore, if somatic genetic changes occur within the
tumor, they too would be responsible for only a component of the
resistance phenotype.
Initial experiments used the 786-O line because the relatively
short time course in which resistance developed allowed for timely
assessment of resistance in multiple rounds of tumor reimplanta-
tion. A498 cell line experiments then allowed for confirmation of
the concept in another cell line in an experiment that more closely
mirrors the clinical situation in which a patient would be exposed
to an antiangiogenic therapy and then have treatment held for
awhile followed by subsequent treatment with the same or a
similar VEGF pathway directed therapy. In this A498 cell line
experiments, we were able to demonstrate the clinically relevant
end-point of re-induction of tumor necrosis and associated
reduction in tumor perfusion on ASL MR imaging with re-
exposure to sorafenib.
These findings are consistent with the mechanism of action of
sorafenib as an inhibitor of VEGFR2. As the likely target of this
agent is the tumor endothelial cell, escape from therapy is likely
due to a compensatory change in the tumor cell perhaps triggered
by hypoxia, leading to activation of alternative means of
supporting angiogenesis. Our biologic data is supported by gene
expression data showing that proangiogenic genes are upregulated
at time of acquired resistance and largely revert following
reimplantion of the resistant tumor into a naı ¨ve host. The changes
we report are likely tumor cell changes as the Affymetrix chip used
was human specific and the cell lines human derived. Thus, while
this data does not exclude a significant contribution from mouse
stromal cells infiltrating the tumor to the resistance mechanism, it
does suggest that any stromal changes may be driven, at least in
part, by treatment induced changes in the tumor cells.
A recent study by Tang et al. shows similar biologic effects of
sorafenib in mouse models of hepatocellular carcinoma (HCC)
[11]. Tang et al found that HCC cell lines that acquired resistance
to sorafenib did not exhibit sustained resistance when reimplanted
into naı ¨ve hosts. Additionally, Hammers et al noted reversal of
epithelial to mesenchymal transition and restored sensitivity to
sunitinib when a patient derived RCC cell line was implanted into
a mouse [12]. The fact that these studies showed similar biologic
effects, suggests that the reversibility of resistance observed with
our two RCC cell lines, may be a more generalizable
phenomenon.
We and others have explored specific mechanisms by which
tumors escape VEGFR blockade and have attempted to implicate
specific genes whose functional inhibition could prevent of delay
the development of resistance phenotype. For example, we have
identified in our transcriptome analysis that interferon gamma
regulated genes are down-modulated with resistance and have
reported that the administration of angiostatic chemokines such as
CXCL9 can delay resistance [13]. In addition, we have seen
upregulation of the expression of sphingosine kinase, an
angiogenic sphingolipid, with resistance and have reported that
disruption of this pathway can slow tumor growth [14].
Additionally, others have shown a role for IL-8 upregulation in
RCC resistance while FGF, PlGF and c-met have been reported to
contribute to VEGF resistance in other tumor models [15–18].
Taken together, this work indicates that resistance is likely to be
complex and multifactorial and that different factors may play a
role in different tumor types or even with different therapies in a
single tumor type. Nonetheless, because of the clinical importance
of VEGF pathway resistance, continued efforts to identify
Figure 5. Serial ASL MRI tumor perfusion of A498 derived tumors. Shown are images of an A498 tumor treated with intermittent sorafenib.
Tumor perfusion after 1 week of therapy is reduced from 119.2 ml/min/100 g to 41.3 ml/min/100 g. Sorafenib was stopped when the tumor became
resistant to sorafenib and tumor perfusion returns after stopping sorafenib (86.9 ml/min/100 g). Sorafenib was restarted after the tumor was allowed
to regrow by 2 mm and then, one week after restarting sorafenib, the tumor was devascularized again (27.3 ml/min/100 g). This entire series was
duplicated in another mouse and similar relative perfusion was noted, thus a representative series is shown. The tumor is indicated by the region of
interest drawn in red and indicated by white arrows.
doi:10.1371/journal.pone.0019144.g005
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warranted.
These data raise several hypotheses for further investigation. For
example, if continued sorafenib exposure leads to a reversible form
of resistance, is it possible that an intermittent administration
schedule might extend the effectiveness of this agent? Additionally,
this data suggests that it might be reasonable to ‘‘rechallenge’’
patients with sorafenib or another VEGF pathway inhibitor
following a defined treatment break. These hypotheses are
supported by clinical observations of antitumor activity seen with
1) sequential administration of VEGF pathway blockers [5,19] 2)
rechallenge with sunitinib after a drug holiday [20], 3) evidence
from the recently reported EFFECT trial that intermittent
sunitinib therapy produces superior efficacy than continuous
therapy [21]. Thus, it is likely that a period off treatment can allow
a tumor to reestablish sensitivity to VEGFR TKI therapy, but
precise dosing schedules at present remain speculative.
While the tumor regains its ability to respond to sorafenib, our
data suggest that some tumor changes in response to sorafenib
are not reversible. Such changes could involve the ability of
tumors to tolerate the angiogenic blockade by modulating their
metabolic needs. While 75% of genes increased in expression
with resistance revert when the tumor is reimplanted into a naı ¨ve
host, the remaining genes whose expression remains perturbed
may be of particular interest. While it is possible that some of
these persistent changes may be the result of treatment derived
mutations within the tumor cells, the fact that they do not block
the restoration of treatment responsive lessens their importance.
Nonetheless, given that there is current evidence in the literature
that antiangiogenic therapy leads to development of more
aggressive tumors [22,23] it is conceivable that some of these
processes may contribute to this altered tumor biology. While our
data show that the ability of sorafenib to decrease tumor blood
flow is reversible, we are in the process of evaluating other
potential effects of therapy that may not be reversible with
reintroduction of antiangiogenic therapy.
The inability to sustain the initial tumor stabilization or
regression induced by VEGF pathway blockers is arguably the
most vexing problem now encountered by oncologists who care for
patients with RCC. This study provides information regarding the
biologic and molecular mechanisms that curtail the initial
effectiveness of VEGFR blockers. We are hopeful that better
understanding of the mechanisms underlying resistance to
VEGFR blockade will enable the creation of treatment schedules
and combination regimens that extend the usefulness of VEGFR
TKIs in patients with RCC and possibly other malignancies that
exhibit sensitivity to anti-angiogenic therapy.
Materials and Methods
Cell Culture
A498 and 786-O, two VHL deficient human RCC cell
lines[20], were obtained from the American Type Culture
Collection (ATCC, Manassas, VA) and cultured for less than
one month with aliquots then frozen. Fresh frozen aliquots were
used for each experiment. A498 was grown in Eagle’s Minimum
Essential Medium (EMEM). 786-O cells were cultured in RPMI
1640 medium (Cellgro). All media was supplemented with 2 mM
L-glutamine, 10% fetal calf serum and 1% streptomycin (50 mg/
ml) and cells were cultured at 37uC with 5% CO2.
Tumor xenograft induction
For subcutaneous xenograft tumor models, female athymic
nude/beige mice (Charles River Laboratories, MA) were used. All
experiments were approved by the Institutional Animal Care and
Use Committee at Beth Israel Deaconess Medical Center. The
mice were housed and maintained in laminar flow cabinets under
specific pathogen-free conditions and throughout the entirety of
the study, all efforts were made to minimize suffering.
Renal cancer cells (786-O or A498) were harvested from
subconfluent cultures by a brief exposure to 0.25% trypsin and
0.02% EDTA. Trypsinization was stopped with medium contain-
ing 10% FBS, and the cells were washed once in serum-free
medium and resuspended in PBS (phosphate buffered saline) as
vehicle. Only suspensions consisting of single cells with greater
than 90% viability were used for the injections.
To establish RCC tumor xenografts, 786-O or A498 tumor
cells were injected subcutaneously (1610
7 cells) into the flanks of
6–8 week old mice that were of 20 gm average body weight.
Tumors developed in .80% of mice and were usually visible
within a few days of implantation. Once they reached a
diameter of 3–5 mm, tumors were measured daily with calipers
to ensure a consistent size at the outset of treatment. Sorafenib
(80 mg/kg, Bayer) was administered 6 out of 7 days per week by
gavage beginning when the tumors had grown to a diameter of
12 mm as previously described [9,25]. Treated and control
tumors were again measured daily during sorafenib therapy.
Tumor long axis was measured and followed to determine
growth curves. 12 mm was used a the prespecificed pretreat-
ment start size in part because this size of tumor size may be
sufficiently large to be comparable to a lesion in human clinical
setting, but not too large to prevent a period of several weeks
before the the mice would need to be sacrificed. It is also an
optimal size for tumor perfusion imaging, which is not easy to
perform on very small tumors. Growth by 2 mm from that size
is the minimal reproducible growth that can be accurately
measured by our calipers. We sought to define the relative
response as the smallest measurable increase in tumor size. This
is the period we have associated with disease stability, similar to
that which is seen in patients as it is roughly equivalent to the
increase in tumor size (20% increase in long axis by RECIST
criteria) that would classify a patient as having progressive
disease (and therefore, treatment resistance) while receiving such
therapy. Treatment was continued until tumors grew to 20 mm
(i.e. the maximum allowable growth by IACUC) at which point
the mice were sacrificed. Tumor tissue was obtained pre-
treatment, during stabilization/response and at time of resis-
tance for various analyses described below.
Tumor reimplantation
786-O tumors that had grown to 20 mm on sorafenib treatment
were harvested in sterile fashion and prepared for reimplantation.
Within 15 minutes of its dissection and removal, the tumor was
homogenized with a tissue homogenizer (PowerGen Model 125;
Fisher Scientific, Waltham, MA) using aseptic technique, and the
tumor cells were washed three times and suspended in sterile PBS
(Mediatech, Inc. Herndon, VA.) for a total volume of 0.4 ml per
injection. The tumor cell suspension was again injected slowly via
a 20-gauge needle subcutaneously into the left flank of mice (1
st re-
implantation group). Animals were monitored and treated as
previously described.
For the second cycle of re-implantation, a reimplanted tumor
that had received a second treatment regimen with sorafenib and
again reached 20 mm was used as a parent tumor for injections to
a third group of naı ¨ve hosts (2
nd reimplantation). Again, the mice
were treated as above the tumors monitored and harvested when
they grew to 20 mm.
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Mice bearing A498 tumors began sorafenib treatment when
tumors reached 12 mm in diameter. Treatment was stopped in
mice when tumors reached 14 mm in diameter and then restarted
in half of the mice after one week (the average time to increase
from 14-16 mm). Perfusion imaging was performed in both groups
after 1 week of treatment and mice were sacrificed and tumors
harvested for histologic review when the tumors reached 20 mm.
Tumors from rechallenged mice were compared to those from
mice either remaining off treatment, on continuous sorafenib or
untreated controls.
RNA extraction
RNA was prepared from frozen 786-O tumors using the Qiagen
RNA extraction kit (Valencia, CA).
Gene Expression Analysis
The transcriptional profile of the excised tumors was charac-
terized by oligonucleotide microarray analysis using the human
U133A plus 2.0 Affymetrix GeneChip, according to previously
described protocols for total RNA extraction and purification,
cDNA synthesis, in vitro transcription for production of biotin-
labeled cRNA, hybridization and scanning of image output files
[26]. The quality of the chip was determined using the
affyQCReport package of Bioconductor [27]. The high quality
arrays were identified on the basis of the scaling factor, average
background, percent present calls and 39/59 RNA ratio for
normalization. The normalization of data was performed using
RMA algorithm in the bioconductor package of R language that
consists of background correction, normalization and summariza-
tion of the signal values [28,29].
A hierarchical clustering technique was used to construct an
Unweighted Pair Group Method with Arithmetic-mean (UPGMA)
tree using Pearson’s correlation as the metric of similarity [30].
The expression data matrix was row-normalized for each gene
prior to the application of average linkage clustering.
Preprocessing and identification of differentially
Expressed genes
The data were filtered by removing all probes that were absent
in all groups of samples e.g. untreated, day 3, resistant and
reimplanted. The Absent/Present/Marginal calls for the tran-
scripts were obtained using MAS5 algorithm [31]. The list of the
differentially expressed genes between any two groups (e.g.
untreated vs. day 3, day 3 vs. resistant) was obtained using the
SAM analysis, an implementation of BRB array tool [32]. The
class comparison was performed with 100 random permutations, a
confidence level of false-discovery rate assessment of 90% and a
maximum allowed proportion of false-positive genes of 5% [33].
All these genes have a low likelihood of being false positives. The
list of the genes yielded by SAM analysis was further refined using
a fold change cutoff of .2 between the control and experimental
group to create final lists of differentially expressed genes.
Geneontology analysis
The Database for Annotation, Visualization and Integrated
Discovery (DAVID) was used to identify over-represented gene
ontology categories form the significantly differentially expressed
genes identified in previous analysis [10]. DAVID is an online
implementation of EASE software that produces the list of over-
represented categories using jackknife iterative resampling of the
Fisher exact probabilities with Bonferroni multiple testing
correction. The EASE score is a significance level with smaller
EASE scores indicating increasing confidence in overrepresenta-
tion. We picked GO categories that have EASE scores of 0.05 or
lower as significantly over-represented.
Complimentary DNA synthesis
Total RNA was converted into cDNA using TaqMan Reverse
Transcription kit (Applied Biosystems Inc., Foster City, CA, USA).
Quantitative real-time PCR analysis
Quantitative real-time PCR (qt-RT-PCR) analysis was per-
formed by a two-step process, a 15-cycle preamplification step
(AmpliTaqH DNA Polymerase Kit; Applied Biosystems Inc.,
Foster City, CA, USA) followed by measurement of mRNA with
an ABI PRISM 7900HT Sequence Detection System. For the
measurement of mRNA levels of 3 genes (angiopoietin like protein
4 (ANGPTL4), matrix metalloprotease 1 (MMP1), serine protease
inhibitor protein 1 (SERPINE1), primers were custom designed
and ordered from IDT (San Diego, CA. The sequences for these
primers are provided in Table S1. For the measurement of mRNA
levels of three genes (neuropilin 2 (NRP2), arginase 2 (ARG2),
insulin-induced gene 1 (INSIG1), the TaqMan probe-primer sets
were commercially purchased (Assay-on-demand, Applied Biosys-
tems, Inc., Foster City, CA, USA). 2x QuantiFast Probe- or SYBR
Green- PCR Master Mix for qt-RT-PCR was purchased from
Qiagen (Valencia, CA, USA). These genes were chosen by their
expression level in the array and the robustness of their differences
in the studies conditions. Amplification was carried out in a total
volume of 20 ml for 40 cycles of 3 seconds at 95uC, 30 seconds at
60uC; initial enzyme activation was performed for 3 min at 95uC.
For normalizing target gene expression, 18s rRNA (house keeping
gene (HKG)) expression was used. The expression measurements
were performed on the RNA extracted from untreated, day3 and
resistant tumors in duplicate. The results are shown as ratio of
target mRNA copy number to 18s rRNA copy number.
Necrosis Assessment
Hematoxylin and Eosin (H&E) stain was performed on formalin
fixed, paraffin embedded tumors and necrosis was assessed. To
quantitate total necrotic area, slides were scanned using the
Scanscope XT (Aperio Technologies Inc., Visa, CA). For each
xenograft tumor, total tumor area as well as areas of necrosis
within the tumor were selected and measured using the
ImageScope Software (Aperio Technologies Inc).
Tumor perfusion imaging
Tumor perfusion imaging (Arterial Spin Labeled [ASL] MRI)
was performed as previously described [9]. Briefly mice were
anaesthetized, and placed in the supine position on a 3 cm in
diameter custom-built surface coil. Adhesive tape was used to limit
movement. Images were acquired using a 3.0 T whole-body
clinical MRI scanner (3T HD; GE Healthcare Technologies,
Waukesha, WI). A single slice ASL image was obtained with a
single-short fast spin echo sequence (SSFSE) using a background-
suppressed, flow-sensitive alternating inversion-recovery strategy.
Twenty-four label and control pair images were acquired and
averaged for the ASL acquisition. A reference proton density
image was acquired by turning off all background suppression and
labeling pulses in the ASL preparation. T1 measurement was
performed after ASL imaging by using the same imaging sequence
at same slice location but with inversion recovery at different
inversion times. The single transversal slice of ASL was carefully
positioned at the center of tumor, which was marked on the skin
with a permanent marker pen for follow-up MRI studies. ASL
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workstation for image reconstruction by using custom software
written within the Interactive Data Language (IDL; research
Systems, Boulder, Co). The ASL difference image, between
average label and control images, was then converted to
quantitative tumor perfusion as previously described [34].
Perfusion was calculated on a pixel-by-pixel basis, and
quantitative maps were produced. The quantitative maps and
the corresponding proton density reference images were then
analyzed by using Image J software (Image Processing and
Analysis in Java; National Institutes of Health, Bethesda, MD). To
determine tumor perfusion, a region of interest was drawn
freehand around the peripheral margin of the tumor by using
an electronic cursor on the reference image that was then copied
to the perfusion image. The mean blood flow for the tumor tissue
within the region of interest was derived, and image window and
level were fixed. A 16-color table was applied in 10 mL/100 g/
min increments ranging from 0 to 160 mL/100 g/min, with flow
values represented as varying shades of black, blue, green, yellow,
red, and purple, in order of increasing perfusion.
Supporting Information
Table S1 Primer Sequences.
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